JP6407028B2 - ＭＲＳＡのＰＢＰ２ａ及びその断片を含むタンパク質、それをコードする核酸、並びにＭＲＳＡ感染を予防する及び治療するための組成物及びそれらの使用 - Google Patents

ＭＲＳＡのＰＢＰ２ａ及びその断片を含むタンパク質、それをコードする核酸、並びにＭＲＳＡ感染を予防する及び治療するための組成物及びそれらの使用 Download PDF

Info

Publication number
JP6407028B2
JP6407028B2 JP2014547351A JP2014547351A JP6407028B2 JP 6407028 B2 JP6407028 B2 JP 6407028B2 JP 2014547351 A JP2014547351 A JP 2014547351A JP 2014547351 A JP2014547351 A JP 2014547351A JP 6407028 B2 JP6407028 B2 JP 6407028B2
Authority
JP
Japan
Prior art keywords
nucleic acid
seq
fragment
protein
pbp2a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014547351A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015501656A5 (enExample
JP2015501656A (ja
Inventor
デイビッド ビー ウェイナー，
デイビッド ビー ウェイナー，
マシュー ピー モロー，
マシュー ピー モロー，
Original Assignee
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア, ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア filed Critical ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
Publication of JP2015501656A publication Critical patent/JP2015501656A/ja
Publication of JP2015501656A5 publication Critical patent/JP2015501656A5/ja
Application granted granted Critical
Publication of JP6407028B2 publication Critical patent/JP6407028B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014547351A 2011-12-12 2012-12-11 ＭＲＳＡのＰＢＰ２ａ及びその断片を含むタンパク質、それをコードする核酸、並びにＭＲＳＡ感染を予防する及び治療するための組成物及びそれらの使用 Expired - Fee Related JP6407028B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161569727P 2011-12-12 2011-12-12
US61/569,727 2011-12-12
PCT/US2012/069014 WO2013090294A1 (en) 2011-12-12 2012-12-11 Proteins comprising mrsa pbp2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat mrsa infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018072242A Division JP2018102319A (ja) 2011-12-12 2018-04-04 ＭＲＳＡのＰＢＰ２ａ及びその断片を含むタンパク質、それをコードする核酸、並びにＭＲＳＡ感染を予防する及び治療するための組成物及びそれらの使用

Publications (3)

Publication Number Publication Date
JP2015501656A JP2015501656A (ja) 2015-01-19
JP2015501656A5 JP2015501656A5 (enExample) 2016-01-21
JP6407028B2 true JP6407028B2 (ja) 2018-10-17

Family

ID=48613118

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014547351A Expired - Fee Related JP6407028B2 (ja) 2011-12-12 2012-12-11 ＭＲＳＡのＰＢＰ２ａ及びその断片を含むタンパク質、それをコードする核酸、並びにＭＲＳＡ感染を予防する及び治療するための組成物及びそれらの使用
JP2018072242A Pending JP2018102319A (ja) 2011-12-12 2018-04-04 ＭＲＳＡのＰＢＰ２ａ及びその断片を含むタンパク質、それをコードする核酸、並びにＭＲＳＡ感染を予防する及び治療するための組成物及びそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018072242A Pending JP2018102319A (ja) 2011-12-12 2018-04-04 ＭＲＳＡのＰＢＰ２ａ及びその断片を含むタンパク質、それをコードする核酸、並びにＭＲＳＡ感染を予防する及び治療するための組成物及びそれらの使用

Country Status (7)

Country Link
US (3) US9750795B2 (enExample)
EP (1) EP2791362B1 (enExample)
JP (2) JP6407028B2 (enExample)
KR (1) KR20140116095A (enExample)
AU (1) AU2012352455B2 (enExample)
CA (1) CA2858884A1 (enExample)
WO (1) WO2013090294A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009158284A2 (en) 2008-06-26 2009-12-30 Mayo Foundation For Medical Education And Research Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
EP4108671B1 (en) 2010-10-01 2024-11-20 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PL3682905T3 (pl) 2011-10-03 2022-04-04 Modernatx, Inc. Modyfikowane nukleozydy, nukleotydy i kwasy nukleinowe oraz ich zastosowania
JP6407028B2 (ja) 2011-12-12 2018-10-17 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ＭＲＳＡのＰＢＰ２ａ及びその断片を含むタンパク質、それをコードする核酸、並びにＭＲＳＡ感染を予防する及び治療するための組成物及びそれらの使用
PL2791160T3 (pl) 2011-12-16 2022-06-20 Modernatx, Inc. Kompozycje zmodyfikowanego mrna
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
RS63237B1 (sr) 2012-11-26 2022-06-30 Modernatx Inc Terminalno modifikovana rnk
EP2971161B1 (en) 2013-03-15 2018-12-26 ModernaTX, Inc. Ribonucleic acid purification
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10590161B2 (en) 2013-03-15 2020-03-17 Modernatx, Inc. Ion exchange purification of mRNA
EP2971033B8 (en) 2013-03-15 2019-07-10 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
EP2971165A4 (en) 2013-03-15 2016-11-23 Moderna Therapeutics Inc DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS
LT3019619T (lt) 2013-07-11 2021-12-10 Modernatx, Inc. Sintetinius polinukleotidus apimančios kompozicijos, koduojančios susijusius su crispr baltymus ir sintetines sgrnas, ir jų naudojimo būdai
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
US10385088B2 (en) 2013-10-02 2019-08-20 Modernatx, Inc. Polynucleotide molecules and uses thereof
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
US10286086B2 (en) 2014-06-19 2019-05-14 Modernatx, Inc. Alternative nucleic acid molecules and uses thereof
CA2955238A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Circular polynucleotides
JP2018527003A (ja) 2015-09-17 2018-09-20 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 安定化尾部領域を含むポリヌクレオチド
US11434486B2 (en) 2015-09-17 2022-09-06 Modernatx, Inc. Polynucleotides containing a morpholino linker
WO2017223176A1 (en) 2016-06-24 2017-12-28 Modernatx, Inc. Methods and apparatus for filtration
IL318736A (en) 2021-06-16 2025-03-01 Conti Innovation Center Llc Mechanically stacked solar transmissive cells or modules
US12414402B1 (en) 2025-01-03 2025-09-09 Conti Innovation Center, Llc Optimizing cadmium (CD) alloy solar cells with sputtered copper-dopped zinc telluride (ZNTE:CU) back contacts in the presence of hydrogen

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1006493A (en) 1911-02-27 1911-10-24 Alwin Mfg Company Folding perambulator or go-cart.
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5223424A (en) 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US5310668A (en) 1986-06-20 1994-05-10 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
US5242829A (en) 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
US5387744A (en) 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
US5294441A (en) 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5112749A (en) 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
AU625584B2 (en) 1989-03-08 1992-07-16 Health Research Inc. Recombinant poxvirus host selection system
EP0465560B1 (en) 1989-03-31 1996-06-05 Washington University VACCINES CONTAINING AVIRULENT phoP-TYPE MICROORGANISMS
DE69016956T2 (de) 1989-12-04 1995-07-20 Akzo Nobel Nv Rekombinantes Truthahn-Herpesvirus und davon abgeleiteter Lebendimpfstoffvektor.
US5294548A (en) 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
US5462734A (en) 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
US5240703A (en) 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
EP0875578A3 (en) * 1991-03-19 1999-05-12 Eli Lilly And Company Penicillin binding protein 2A from staphylococcus aureus strain 27R and derivatives for use in purification therefor and assay for compounds effective against methicillin resistant organisms
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
DE69434469T2 (de) 1993-01-26 2006-06-14 Univ Pennsylvania Zusammensetzungen und verfahren zur verabreichung von genetischem material
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
DK1023107T3 (da) 1997-04-03 2006-12-27 Electrofect As Fremgangsmåde til indgivelse af farmaceutiske præparater og nucleinsyrer i skeletmuskulaturen
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
HUP0004589A3 (en) 1997-06-30 2003-08-28 Centre Nat Rech Scient Improved method for transferring nucleic acid into the striped muscle and combination therefor
US7060458B1 (en) * 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
EP2428250A1 (en) 1998-07-13 2012-03-14 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
EP1233974A4 (en) * 1999-09-01 2004-09-22 Human Genome Sciences Inc GENES AND POLYPEPTIDEDES 37 I STAPHYLOCOCCUS AUREUS / I
JP4472250B2 (ja) * 2000-10-04 2010-06-02 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 高発現可能遺伝子
JP3543326B2 (ja) 2001-08-30 2004-07-14 ソニー株式会社 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
TWI290174B (en) 2002-11-04 2007-11-21 Advisys Inc Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
ES2748130T3 (es) 2003-05-30 2020-03-13 Vgxi Inc Dispositivos y métodos para la producción de un biomaterial
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
KR102334637B1 (ko) * 2006-07-28 2021-12-06 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 백신 및 이의 사용 방법
WO2008154101A1 (en) 2007-06-06 2008-12-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Psm peptides as vaccine targets against methicillin-resistant staphylococcus aureus
JP5788676B2 (ja) * 2008-01-11 2015-10-07 イノビオ ファーマシューティカルズ，インコーポレイティド デングウイルスの複数のサブタイプに対する新規ワクチン
JP2009222712A (ja) * 2008-02-21 2009-10-01 Univ Nagoya メチシリン耐性ブドウ球菌の検出法、検出用試薬及び検出用キット
WO2009158284A2 (en) * 2008-06-26 2009-12-30 Mayo Foundation For Medical Education And Research Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance
WO2010057155A1 (en) 2008-11-17 2010-05-20 Enzon Pharmaceuticals, Inc. Releasable cationic lipids for nucleic acids delivery systems
CA2740598C (en) * 2008-11-17 2018-05-22 Mathura P. Ramanathan Antigens that elicit immune response against flavivirus and methods of using same
EP4108671B1 (en) 2010-10-01 2024-11-20 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP6407028B2 (ja) 2011-12-12 2018-10-17 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ＭＲＳＡのＰＢＰ２ａ及びその断片を含むタンパク質、それをコードする核酸、並びにＭＲＳＡ感染を予防する及び治療するための組成物及びそれらの使用
GB2504774A (en) 2012-08-10 2014-02-12 Munster Simms Eng Ltd Diaphragm pump with integral motor housing and rear pump housing
TWI548337B (zh) 2015-10-16 2016-09-01 技嘉科技股份有限公司 散熱模組、顯示卡組件及電子裝置

Also Published As

Publication number Publication date
US20190030155A1 (en) 2019-01-31
EP2791362B1 (en) 2019-07-03
AU2012352455B2 (en) 2016-01-21
CA2858884A1 (en) 2013-06-20
CN104254616A (zh) 2014-12-31
AU2012352455A1 (en) 2014-06-26
HK1205201A1 (en) 2015-12-11
US9750795B2 (en) 2017-09-05
WO2013090294A1 (en) 2013-06-20
US10064931B2 (en) 2018-09-04
US20180028640A1 (en) 2018-02-01
EP2791362A4 (en) 2015-07-15
KR20140116095A (ko) 2014-10-01
JP2015501656A (ja) 2015-01-19
US20140341944A1 (en) 2014-11-20
US10980870B2 (en) 2021-04-20
EP2791362A1 (en) 2014-10-22
JP2018102319A (ja) 2018-07-05

Similar Documents

Publication Publication Date Title
JP6407028B2 (ja) ＭＲＳＡのＰＢＰ２ａ及びその断片を含むタンパク質、それをコードする核酸、並びにＭＲＳＡ感染を予防する及び治療するための組成物及びそれらの使用
JP6333730B2 (ja) 改善されたｉｌ−１２遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法
CN103354750A (zh) 共有抗原构建体和由其制备的疫苗以及使用所述疫苗治疗疟疾的方法
US10953079B2 (en) Synthetic immunogens for prophylaxis or treatment of tuberculosis
JP6525949B2 (ja) ボツリヌス菌の各血清型の重鎖を使用する１価または多価のボツリヌス神経毒素ワクチン
CN104254616B (zh) 包含mrsa pbp2a及其片段的蛋白、编码它们的核酸、以及组合物及它们预防和治疗mrsa感染的用途
HK1205201B (en) Proteins comprising mrsa pbp2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat mrsa infections
HK1234438B (zh) 共有前列腺抗原、編碼所述抗原的核酸分子以及包含所述核酸分子的疫苗及其用途
HK1190329A (en) Consensus antigen constructs and vaccines made therefrom, and methods of using same to treat malaria

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170731

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180404

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180816

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180828

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180918

R150 Certificate of patent or registration of utility model

Ref document number: 6407028

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees